$1.61
-0.17 (-9.55%)
Open$1.72
Previous Close$1.78
Day High$1.73
Day Low$1.60
52W High$9.50
52W Low$1.28
Volume—
Avg Volume118.5K
Market Cap55.49M
P/E Ratio—
EPS$-10.60
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,271.4% upside
Current
$1.61
$1.61
Target
$22.08
$22.08
$13.69
$22.08 avg
$22.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.10M | 11.96M | 10.98M |
| Net Income | 3.15M | 2.42M | 2.50M |
| Profit Margin | 26.0% | 20.2% | 22.8% |
| EBITDA | 4.53M | 4.37M | 3.74M |
| Free Cash Flow | 1.56M | 1.43M | 1.67M |
| Rev Growth | +0.7% | +19.7% | +24.9% |
| Debt/Equity | 0.93 | 0.73 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |